Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (336)

2024

  1. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

    Haematologica, Vol. 109, Núm. 3, pp. 867-876

  2. Bicaval TricValve Implantation in Patients With Severe Symptomatic Tricuspid Regurgitation: 1-Year Follow-Up Outcomes

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 1, pp. 60-72

  3. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94

  4. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

  5. Germline assessment for alloHSCT candidates over 50 years: A ‘Fast-Track’ screening in myeloid neoplasms

    British Journal of Haematology

  6. Improving the Access of Highly Sensitized Patients to Kidney Transplantation From Deceased Donors: The Spanish PATHI Program With Allocation Based on the Virtual Crossmatch

    Transplantation, Vol. 108, Núm. 3, pp. 787-801

  7. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction – a randomized trial: The NICE study

    European Journal of Heart Failure

  8. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

  9. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

    Cancer

  10. T-cell immune profile in blood of systemic mastocytosis: Association with disease features

    Allergy: European Journal of Allergy and Clinical Immunology

  11. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

  12. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology

  13. [Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 3, pp. T237-T245

2023

  1. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

    ERJ Open Research, Vol. 9, Núm. 6

  2. Associations of hypomagnesemia in patients seeking a first treatment of alcohol use disorder

    Drug and Alcohol Dependence, Vol. 245

  3. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

    Haematologica, Vol. 108, Núm. 1, pp. 110-121

  4. Breakthrough invasive fungal infection among patients with haematologic malignancies: A national, prospective, and multicentre study

    Journal of Infection, Vol. 87, Núm. 1, pp. 46-53

  5. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  6. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  7. Coronary Obstruction After Transcatheter Aortic Valve Replacement: Insights From the Spanish TAVI Registry

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 10, pp. 1208-1217